Anne Kristine Anstensrud

  • PhD fellow; MD
 

Publications 2024

Holme FA, Huse C, Kong XY, Broch K, Gullestad L, Anstensrud AK, Andersen GØ, Amundsen BH, Kleveland O, Quiles-Jimenez A, Holm S, Aukrust P, Alseth I, Halvorsen B, Dahl TB (2024)
Circular RNA Profile in Atherosclerotic Disease: Regulation during ST-Elevated Myocardial Infarction
Int J Mol Sci, 25 (16)
DOI 10.3390/ijms25169014, PubMed 39201700

Hunt TEF, Traaen GM, Aakerøy L, Massey RJ, Bendz C, Øverland B, Akre H, Steinshamn S, Loennechen JP, Broch K, Helle-Valle T, Lie ØH, Anstensrud AK, Haugaa KH, Gullestad L, Anfinsen OG, Aakhus S (2024)
Cardiac remodelling in patients with atrial fibrillation and obstructive sleep apnoea
Open Heart, 11 (2)
DOI 10.1136/openhrt-2024-002718, PubMed 39477342

Kindberg KM, Broch K, Andersen GØ, Anstensrud AK, Åkra S, Woxholt S, Tøllefsen IM, Ueland T, Amundsen BH, Kløw NE, Halvorsen B, Dahl TB, Huse C, Murphy SL, Damås JK, Opdahl A, Wiseth R, Gullestad L, Aukrust P, Santos-Gallego C, Seljeflot I, Stokke MK, Helseth R (2024)
Neutrophil Extracellular Traps in ST-Segment Elevation Myocardial Infarction: Reduced by Tocilizumab and Associated With Infarct Size
JACC Adv, 3 (9), 101193
DOI 10.1016/j.jacadv.2024.101193, PubMed 39247678

Woxholt S, Ueland T, Aukrust P, Anstensrud AK, Broch K, Tøllefsen IM, Seljeflot I, Halvorsen B, Dahl TB, Huse C, Andersen GØ, Gullestad L, Wiseth R, Damås JK, Kleveland O (2024)
Effect of tocilizumab on endothelial and platelet-derived CXC-chemokines and their association with inflammation and myocardial injury in STEMI patients undergoing primary PCI
Int J Cardiol, 418, 132613
DOI 10.1016/j.ijcard.2024.132613, PubMed 39374793

Publications 2023

Woxholt S, Ueland T, Aukrust P, Anstensrud AK, Broch K, Tøllefsen IM, Ryan L, Bendz B, Hopp E, Kløw NE, Seljeflot I, Halvorsen B, Dahl TB, Huse C, Andersen GØ, Gullestad L, Wiseth R, Amundsen BH, Damas JK, Kleveland O (2023)
Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab
Open Heart, 10 (2)
DOI 10.1136/openhrt-2023-002301, PubMed 37591633

Publications 2022

Huse C, Anstensrud AK, Michelsen AE, Ueland T, Broch K, Woxholt S, Yang K, Sharma K, Tøllefsen IM, Bendz B, Amundsen BH, Damås JK, Berg ES, Bjørkelund E, Quiles-Jiménez A, Bjerkeli V, Bendz C, Kleveland O, Stensaeth KH, Opdahl A, Kløw NE, Andersen GØ, Wiseth R, Halvorsen B, Gullestad L et al. (2022)
Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial
EBioMedicine, 80, 104013
DOI 10.1016/j.ebiom.2022.104013, PubMed 35504178

Publications 2021

Broch K, Anstensrud AK, Woxholt S, Andersen GØ, Gullestad L (2021)
Reply: Clarification Regarding the Lack of Heart Failure Events in the ASSAIL-MI Trial
J Am Coll Cardiol, 78 (6), 637-638
DOI 10.1016/j.jacc.2021.06.005, PubMed 34353542

Broch K, Anstensrud AK, Woxholt S, Sharma K, Tøllefsen IM, Bendz B, Aakhus S, Ueland T, Amundsen BH, Damås JK, Berg ES, Bjørkelund E, Bendz C, Hopp E, Kleveland O, Stensæth KH, Opdahl A, Kløw NE, Seljeflot I, Andersen GØ, Wiseth R, Aukrust P, Gullestad L (2021)
Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction
J Am Coll Cardiol, 77 (15), 1845-1855
DOI 10.1016/j.jacc.2021.02.049, PubMed 33858620

Publications 2020

Anstensrud AK, Molden E, Haug HJ, Qazi R, Muriq H, Fosshaug LE, Spigset O, Øie E (2020)
Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study
Eur J Clin Pharmacol, 76 (5), 673-683
DOI 10.1007/s00228-020-02832-0, PubMed 31940084

Publications 2019

Anstensrud AK, Woxholt S, Sharma K, Broch K, Bendz B, Aakhus S, Ueland T, Amundsen BH, Damås JK, Hopp E, Kleveland O, Stensæth KH, Opdahl A, Kløw NE, Seljeflot I, Andersen GØ, Wiseth R, Aukrust P, Gullestad L (2019)
Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)
Open Heart, 6 (2), e001108
DOI 10.1136/openhrt-2019-001108, PubMed 31673391

Fosshaug LE, Colas RA, Anstensrud AK, Gregersen I, Nymo S, Sagen EL, Michelsen A, Vinge LE, Øie E, Gullestad L, Halvorsen B, Hansen TV, Aukrust P, Dalli J, Yndestad A (2019)
Early increase of specialized pro-resolving lipid mediators in patients with ST-elevation myocardial infarction
EBioMedicine, 46, 264-273
DOI 10.1016/j.ebiom.2019.07.024, PubMed 31345784